# Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer

> **NCT05253066** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Shengjing Hospital** · enrollment: 130 (estimated)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Chidamide combined with exemestane (+/- goserelin)
- **DRUG:** Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)

## Key facts

- **NCT ID:** NCT05253066
- **Lead sponsor:** Shengjing Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-25
- **Primary completion:** 2022-07-31
- **Final completion:** 2025-01-31
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2022-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05253066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05253066, "Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05253066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*